Welcome to our dedicated page for Envista Holdings news (Ticker: NVST), a resource for investors and traders seeking the latest updates and insights on Envista Holdings stock.
Envista Holdings Corporation reports recurring developments as a global dental products company serving dental professionals through consumables, technologies, equipment and services. Its public updates center on quarterly results, core sales trends, adjusted earnings measures, cash flow, share repurchase activity and management presentations at healthcare conferences.
Company news also covers product and brand activity across DEXIS, Kerr, Nobel Biocare and Ormco, including dental implants, orthodontics, digital imaging, restorative and endodontic solutions. Recent product announcements include Kerr Dental's ZenSeal Pro with ZenSave Tips, reflecting Envista's focus on dental workflow, treatment technology and clinician-facing product commercialization.
Envista Holdings Corporation (NYSE: NVST) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, from 3:00 – 3:40 PM PT at the Westin St. Francis Hotel in San Francisco. Investors can access a live audio webcast and recording on Envista's Investor Relations website for 30 days post-event. Envista is a leading global dental products company with a portfolio of over 30 trusted dental brands, including Nobel Biocare and Ormco, focused on improving lives through innovative dental solutions and technology.
On November 7, 2022, Envista Holdings Corporation (NYSE: NVST) announced its upcoming participation in the Evercore ISI 5th Annual HEALTHCONx Conference. The virtual event will take place on November 30, 2022, from 11:20 AM to 12:05 PM ET. Investors can access live streams and recordings via Envista's Investor Relations website under Events and Presentations. Envista, a leading global dental products company, offers a diverse portfolio including dental implants, orthodontics, and digital imaging technologies, aimed at enhancing patient care.
Envista Holdings Corporation (NYSE: NVST) reported a 3.9% increase in sales for Q3 2022, totaling $631.1 million. Core sales growth stood at 4.9% compared to Q3 2021. Net income reached $49.6 million, translating to $0.28 per diluted share, while adjusted net income improved to $82.5 million or $0.47 per diluted share. Adjusted EBITDA rose to $127.6 million, reflecting a 20.2% margin. Despite economic challenges, the company maintains its guidance for mid-single-digit core sales growth and a 20% adjusted EBITDA margin for 2022.
Envista Holdings Corporation (NYSE: NVST) announced its participation in the Jefferies London Healthcare Conference on November 17, 2022, from 9:45 - 10:15 AM GMT. Investors can access audio recordings of the event via the Investor Relations section on Envista's website. Envista, a leading global dental products company with over 30 renowned brands, focuses on enhancing patient care through innovative solutions and services.
Summary not available.
Envista Holdings Corporation (NYSE: NVST) will announce its third quarter 2022 financial results on November 3, 2022. A conference call is scheduled for the same day at 2:00 PM PT, expected to last approximately one hour. The results and related materials will be available on the company's website prior to the call. Envista is a global leader in dental products, encompassing more than 30 trusted brands and providing a comprehensive range of dental solutions.
Envista Holdings Corporation (NYSE: NVST) will join the Piper Sandler MedTech and Diagnostics California Bus Tour on August 24, 2022, from 10:00 to 10:50 AM PT in Laguna Niguel, California. This in-person event will not be webstreamed. Envista, a leading global dental products company with over 30 trusted brands, focuses on improving patient care through its comprehensive portfolio, including dental implants, orthodontics, and digital imaging technologies. The company aims to meet the diverse clinical needs of dental professionals worldwide.
Envista Holdings Corporation (NYSE: NVST) reported a 1.3% sales increase to $645.8 million for Q2 2022, with core sales growth of 4%. Net income reached $44.5 million ($0.25 per diluted share), while adjusted net income was $86 million ($0.48 per diluted share), up from $0.46 in Q2 2021. Adjusted EBITDA rose to $126.9 million. CEO Amir Aghdaei noted ongoing supply chain challenges and geopolitical uncertainties but highlighted success in acquisitions, namely Carestream Dental's IOS business and Osteogenics' solutions. However, the company adjusted its 2022 guidance, anticipating mid-single digit core sales growth.
Envista Holdings announced an extension of its partnership with dentalcorp, Canada's largest dental service organization. This collaboration aims to enhance implant treatment capabilities across over 500 dentalcorp practices. Nobel Biocare, a subsidiary of Envista, will provide comprehensive support and training to more than 1,500 dentists within dentalcorp's network. This partnership emphasizes Envista's commitment to supporting dental professionals and improving patient care, focusing on digital and personalized solutions in the dental sector.
Envista Holdings Corporation (NYSE: NVST) will announce its financial results for Q2 2022 on August 3, 2022. A conference call is scheduled for 2:00 PM PT that same day, accessible via phone or webcast. Investors can expect a detailed discussion of the results, which will be accompanied by a slide presentation available on Envista's website. This call aims to provide insights into the company's performance, reflecting its commitment to enhancing customer care through a comprehensive range of dental solutions.